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ABSTRACT
Objective:To review the incidence ofneonatal group B streptococcal (GBS) sepsis and its associated
risk factors in our obstetrical population.
Methods: A computerized perinatal database of over 17,000 births (from 1992 to 1996) was
queried for the incidence of neonatal GBS sepsis. A more detailed review of 895 births (from the
first quarter of 1997) was undertaken to identify the incidence of risk factors known to be associated
with neonatal GBS sepsis.
Results: In our institution, 30 cases of neonatal early-onset GBS sepsis were identified in
over 17,000 births (or 1.7/1,000 deliveries). Risk factors were identified in 17 of those cases
(56%). There were two neonatal fatalities. Chemoprophylaxis was provided in 15% of the total
deliveries.
Conclusions: In spite of the lack of a uniform policy for identifying patients suitable for GBS
chemoprophylaxis, we found only a 43% incidence of neonatal GBS sepsis occurring without risk
factors present. Identification of antepartum or intrapartum risk factors in our series, therefore,
would have identified the majority of cases resulting in neonatal GBS sepsis, which may have
benefited from intrapartum therapy. Some negative potential consequences of chemoprophylaxis
are discussed, raising questions regarding the recent recommendations of the Centers for Disease
Control and Prevention. Infect. Dis. Obstet. Gynecol. 6:25-29, 1998. (C) 1998 Wiley-Liss, Inc.
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he risk of perinatal genital carriage of group B
streptococcus (GBS) ranges from about 10-
30%, depending on the manner in which screening
cultures are performed and the populations
screened. 1,2 The risk of vertical transmission of
GBS from such mothers yielding early-onset neo-
natal sepsis is about .5%, and the risk of mortality
from this sepsis is currently about 15%.3-6 The
overall risk of neonatal mortality from GBS sepsis is
therefore about 1--4 per 10,000 births. The Centers
for Disease Control and Prevention (CDC) has rec-
ommended either one of two protocols for the pre-
vention of this serious outcome,7 though no ran-
domized studies exist which show the two proto-
cols to be equivalent in efficacy. Numerous studies
have shown the efficacy of intrapartum chemopro-
phylaxis in preventing neonatal GBS,4,8,9 though
the question remains as to which parturients would
benefit most from this chemoprophylaxis: those
with documented GBS cervical carriage, those with
identified risk factors, or both.
At our institution, there are private and public
patients. Therefore, intrapartum management var-
ies, and intrapartum chemoprophylaxis has been
provided to those women with identified risk fac-
tors, as well as those who were found to be GBS-
positive antepartum. As such, there has not been a
consistent manner of management of GBS risk at
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TABLE I. Deliveries from January through March,
1997 (n 895)
Prophylaxis
Risk factors for GBS neonatal sepsis No. given, no. (%)
Prematurity 169 19 (I I%)
Prolonged rupture of membranes 83 8 (10%)
Intrapartum fever 10 (91%)
Previous child with GBS sepsis 0 0 (0%)
aGBS, group B streptococcus.
our institution over the past five years. The risk of
neonatal GBS can, nonetheless, be determined, ir-
respective of antibiotic use.
We conducted a retrospective review of over
17,000 deliveries with respect to the incidence of
GBS neonatal sepsis in our institution. Thirty cases
of early-onset invasive GBS neonatal sepsis were
found and analyzed. It is the intent of this report to
1) examine the risk of GBS neonatal sepsis in our
population, 2) compare the stated risk in our popu-
lation with others, and 3) consider the practicality
of strategies for the management of GBS risk in
populations similar to ours.
METHODS
Our own proprietary computerized perinatal data-
base of 17,867 births dating from January 1, 1992,
to December 31, 1996, was queried for the inci-
dence of neonatal sepsis. Specific medical records
were selected for review, and 30 cases were found
to have involved GBS sepsis, including positive
blood and/or cerebrospinal fluid cultures. The ap-
propriate maternal medical records were then re-
viewed to see if any risk factors existed for the
vertical transmission of GBS.
As the details were more readily available for a
recent single quarter (January-March 1997), the
medical records of the 895 deliveries that occurred
during that time period were looked at to ascertain
the percentage of patients with intrapartum risk
factors who did and did not receive intrapartum
chemoprophylaxis (see Table 1). In addition, these
same records were reviewed to determine the
length of time between the admission of the pa-
tient to the labor and delivery unit and delivery.
RESULTS
The 30 maternal cases that were delivered in our
institution from 1992 to 1996 in which early-onset
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GBS neonatal sepsis occurred (1.7/1,000 deliveries)
are listed in Table 2. At least one risk factor was
identified in 17 of those cases (57%). There were
two neonatal fatalities in this group. Intrapartum
chemoprophylaxis with intravenous ampicillin was
given in one of the cases, indicated because of the
presence of identified risk factors, and initiated
more than four hours prior to delivery. Neonatal
GBS sepsis occurred in this case despite the che-
moprophylaxis provided.
Of the 895 deliveries between January 1, 1997,
and March 31, 1997, there were 234 (26%) cases in
which one or more intrapartum risk factors were
identified (listed in Table 1). In 34 (15%) of those
cases, intrapartum antimicrobial chemoprophylaxis
was given. Ampicillin was generally the drug of
choice, except in cases of intrapartum fever, when
a broader spectrum antibiotic was used, such as
cefoxitin. In addition, the same 895 cases from the
first quarter of 1997 were reviewed to identify
those deliveries that occurred within one hour from
the time of admission. Eighty-two (9%) such cases
were identified.
DISCUSSION
Multiple studies have shown that antepartum geni-
tal cultures are imprecise in predicting GBS genital
carriage at delivery, given the intermittent nature
of the genital carriage of GBS. 1,1-13 It is the pres-
ence or absence ofGBS at the time of delivery that
determines the risk of its perinatal transmission.
While the parturient identified as a GBS carrier is
best treated with intrapartum antimicrobial chemo-
prophylaxis to minimize the risk of resultant GBS
neonatal sepsis,6,8 it is not successful every time it
is used, as is suggested by our own data.
Following one of the two CDC protocols calling
for the intrapartum antimicrobial treatment of
women found to be GBS positive antepartum
would result in at least 15% of all parturients being
treated (potentially 600,000 women annually in the
United States). This would be done in an attempt
to reduce neonatal mortality from the current rate
of 1-4 per 10,000 deliveries. Aside from consider-
ations of cost, attention should be paid to the pos-
sibility of causing excess morbidity and mortality as
a result of this screening. One such source of this
morbidity and mortality is the risk of anaphylaxis.
It has been estimated that one fatality can be ex-RISK AND MANAGEMENT OF GROUP B STREP LEVINE ET AL.
TABLE 2. Maternal cases
GBS Prophylaxis/Treatment
ID positive given Preterm
Prolonged
rupture of Intrapartum Previous baby
membranes fever with GBS
MR ND N N N N N
NH ND N N N Y N
LG ND N N N N N
TK ND Y N N Y N
ML ND N N N N N
MC ND N N N N N
JJ ND N Y N N N
NN ND N N N N N
ME ND N Y N N N
CT ND N N N N N
SA ND N N N Y N
JD ND N N Y N N
GJ ND N N Y N N
PL ND N Y N N N
JL ND N N N N N
DE} ND N N N N N
PR ND N N Y N N
NG ND Y N Y Y N
AG ND N N N N N
PG ND N Y N N N
DD ND Y N Y Y N
MP ND N Y N N N
MA ND N N N N N
CR ND N N N N N
LB ND N Y Y N N
GP ND N N N Y N
YA ND N N Y N N
MC ND N N N N N
CS ND N Y N N N
MC ND N N N N N
aGBS, group B streptococcus.
bND, Not determined.
CNeonatal death.
pected for every 100,000 patients treated with
penicillin. 14,1s Extrapolating from this estimate, it
appears that six women could die annually if the
CDC’s recommendation were followed. It should
be further emphasized that the fetus can also be
adversely affected in anaphylactic reactions, as has
been reported. 16,17
Additionally, the volume of antibiotic use rec-
ommended by such a protocol will undoubtedly
have an impact on the emergence of resistant bac-
terial strains. It is not unreasonable to assume such
antimicrobial selective pressure will inevitably
cause the antibiotics that we currently use for the
treatment of streptococcal bacterial infections to be
less effective in the future. Such changes in the
patterns of bacterial resistance have been seen
against ampicillin by Escherichia coli and against
penicillin by Neisseria gonorrhoeae and, more re-
cently, by Streptococcus pneumoniae. 1s-z
Just as the CDC protocol recommends prophy-
laxis for GBS carriers without risk factors (not jus-
tified by the objective studies performed by Boyer
et al.Z,4,s), the CDC recommendation will likely
cause practitioners to provide prophylaxis for GBS
carriers and those with risk factors as well. Medi-
colegal concerns will likely provide the impetus for
this. While it is important to obtain informed con-
sent from patients regarding methods of selection
for GBS prophylaxis, one must wonder what can be
explained to a patient, given that there are no data
to justify using one method versus another.
As a practical matter, if a patient who is identi-
fied as a GBS carrier delivers within one hour of
admission, the antibiotic given such a patient will
likely be ineffective in preventing neonatal GBS
sepsis,z This is, of course, assuming that all such
patients are even properly identified when they are
admitted to the labor and delivery suite. In our
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study, 9% of patients would fall into this category.
It can be estimated, then, that 9% of those women
found to be GBS carriers would not be adequately
treated during labor because of their "late" arrival
to labor and delivery. This would offer a practical
limitation on the effectiveness of antepartum GBS
screening.
In our study, an antepartum genital culture
would have had to be performed for almost 18,000
patients to identify those GBS carriers who should
receive intrapartum antimicrobial prophylaxis in an
attempt to prevent the additional 13 cases of GBS
sepsis in babies born to women without risk factors.
These numbers become important when consider-
ing GBS prevention strategies and their attendant
risks. It should be noted that the incidence of GBS
neonatal sepsis in our series is 1.7/1,000 deliveries,
which is similar to that reported elsewherezz,z3
when intrapartum chemoprophylaxis is not given.
Also, it was noted that 26% of the patients deliv-
ering in the first quarter of 1997 had risk factors for
GBS, as opposed to the 18% reported by Boyer et
al. z This may be due to the fact that our institution
is a tertiary care facility drawing a population at
higher risk than that seen elsewhere. Also, our fig-
ure includes 52 patients who were, by definition,
preterm at delivery, yet at greater than 36 weeks of
gestation, a gestational age at which many practi-
tioners may choose not to offer prophylaxis.
Clinicians have been taught to "First, do no
harm." It seems that the potential for harm from
GBS screening may not have been adequately con-
sidered, or it may have been underestimated. Fu-
ture studies will hopefully provide additional in-
sights into the clinical process of GBS prevention
with an eye towards its practical aspects. This
would be a valuable addition to the various relevant
decision analyses recently performedz4,z5 and
would help promote evidence-based clinical prac-
tice.
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